In summary, it is reasonable that immunotherapy epical anti-PD-1/PD-L1 therapy may change the neoadjuvant therapeutic foreground of CRC and ultimately achieve the goal of patient benefit. This evidence concerns the gene PDCD1 and colorectal carcinoma.